Technological advancements and future perspectives in breast cancer radiation therapy.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2023-04-01 DOI:10.1080/14737140.2023.2195167

Alessandra Fozza, Fiorenza De Rose, Maria Carmen De Santis, Icro Meattini, Bruno Meduri, Elisa D'angelo, Damiano Dei, Vanessa Figlia, Eliana La Rocca, Piero Fregatti, Camilla Satragno, Liliana Belgioia, Niccolò Giaj-Levra

{"title":"Technological advancements and future perspectives in breast cancer radiation therapy.","authors":"Alessandra Fozza, Fiorenza De Rose, Maria Carmen De Santis, Icro Meattini, Bruno Meduri, Elisa D'angelo, Damiano Dei, Vanessa Figlia, Eliana La Rocca, Piero Fregatti, Camilla Satragno, Liliana Belgioia, Niccolò Giaj-Levra","doi":"10.1080/14737140.2023.2195167","DOIUrl":null,"url":null,"abstract":"Introduction: Breast cancer is still one of the most common tumors worldwide and radiation therapy has a central role in the oncological pathway. Several technological options are now available with the aim to improve therapeutic index, target definition, and patient selection.Areas covered: In this review, we summarize current available technologies in the management of breast cancer. These advances can support the prescription of postoperative partial breast cancer treatment and preoperative stereotactic partial breast irradiation. Moreover, image-guided radiotherapy is crucial for high-quality radiation treatments. Additionally, the recent development of hybrid magnetic resonance linear accelerator can impact target volume outline procedure, adaptive planning and radiomics. Finally, artificial intelligence represents the new frontier in medicine, supporting clinicians in target definition, patient selection, and treatment planning.Expert opinion: In patients with breast cancer the overall level of evidence about new technologies is still low even if some advances are potentially very interesting to further development.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":"23 4","pages":"407-419"},"PeriodicalIF":2.9000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2023.2195167","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction: Breast cancer is still one of the most common tumors worldwide and radiation therapy has a central role in the oncological pathway. Several technological options are now available with the aim to improve therapeutic index, target definition, and patient selection.

Areas covered: In this review, we summarize current available technologies in the management of breast cancer. These advances can support the prescription of postoperative partial breast cancer treatment and preoperative stereotactic partial breast irradiation. Moreover, image-guided radiotherapy is crucial for high-quality radiation treatments. Additionally, the recent development of hybrid magnetic resonance linear accelerator can impact target volume outline procedure, adaptive planning and radiomics. Finally, artificial intelligence represents the new frontier in medicine, supporting clinicians in target definition, patient selection, and treatment planning.

Expert opinion: In patients with breast cancer the overall level of evidence about new technologies is still low even if some advances are potentially very interesting to further development.

查看原文本刊更多论文

乳腺癌放射治疗的技术进步和未来展望。

乳腺癌仍然是世界范围内最常见的肿瘤之一，放射治疗在肿瘤通路中起着核心作用。现在有几种技术选择，目的是改善治疗指数、目标定义和患者选择。涵盖领域:在这篇综述中，我们总结了目前在乳腺癌管理中可用的技术。这些进展可以支持乳腺癌术后部分治疗和术前立体定向部分乳房照射的处方。此外，图像引导放射治疗对于高质量的放射治疗至关重要。此外，近年来发展起来的混合磁共振直线加速器可以影响靶体积轮廓程序、自适应规划和放射组学。最后，人工智能代表了医学的新前沿，在目标定义、患者选择和治疗计划方面支持临床医生。专家意见:在乳腺癌患者中，新技术的总体证据水平仍然很低，即使一些进展对进一步发展可能非常有趣。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.